<DOC>
	<DOCNO>NCT01674309</DOCNO>
	<brief_summary>The FOLFIRINOX protocol seem promise protocol attack treatment rectum cancer , objective response rate 70 % . This phase II investigate systematic attack chemotherapy could control time rectal tumor synchronous metastasis without compromise secondarily tumor metastasis resection radiochemotherapy administration . 1 . The main objective trial investigate tumoral control rate 4 month , accord RECIST criterion ( version 1.1 ) . 2 . The secondary objective : - safety treament , - rate local failure local complication ( occlusion , important bleeding , resistant pain morphinic treatment , perforation ) , - survival without local failure ( radiological clinical progression rectal cancer local complication ) , - rectal tumor response rate ( CT scan , MRI endocopy ) , - metastasis response rate , - disease free survival complete resection ( primitive tumor metastasis ) , - progression free survival ( local distal ) , - overall survival , quality life ( QLQ-C30 + CR 29 ) .</brief_summary>
	<brief_title>First Line Treatment FOLFIRINOX Patients With Rectum Cancer With Synchronous Non Resectable Metastasis</brief_title>
	<detailed_description>The FOLFIRINOX protocol seem promise protocol attack treatment rectum cancer , objective response rate 70 % . This phase II investigate systematic attack chemotherapy could control time rectal tumor synchronous metastasis without compromise secondarily tumor metastasis resection radiochemotherapy administration . 1 . The main objective trial investigate tumoral control rate 4 month , accord RECIST criterion ( version 1.1 ) . 2 . The secondary objective : - safety treament , - rate local failure local complication ( occlusion , important bleeding , resistant pain morphinic treatment , perforation ) , - survival without local failure ( radiological clinical progression rectal cancer local complication ) , - rectal tumor response rate ( CT scan , MRI endocopy ) , - metastasis response rate , - disease free survival complete resection ( primitive tumor metastasis ) , - progression free survival ( local distal ) , - overall survival , quality life ( QLQ-C30 + CR 29 ) . 3 . Inclusion non inclusion criterion 4 . Treatment 5 . Follow</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>Histologically proven adenocarcinoma rectum , low pole less 15 cm anal verge Patient receive treatment cancer Synchronous metastases unresectable hepatic and/or lung localization uncertain resectability ( potentially resectable ) Measurable lesion RECIST 1.1 ( metastasis primary cancer rectum ) Age ≥ 18 year WHO ≤ 2 ANC ≥ 1.5 x 10 9/L , platelet ≥ 100 x 10 9/L , creatinine clearance ≥ 60 mL/min Hemoglobin ≥ 10 g /dL Signed informed consent Rectal Cancer occlusion require surgery prosthesis emergency Rectal bleeding severe active Prior pelvic irradiation History cancer , except nonmelanoma skin cancer , carcinoma situ cervix treat curatively cancer treat curatively relapse 3 year , Hepatic impairment ( total bilirubin &gt; 1.5 x upper limit normal ( ULN ) serum albumin &lt; 25g / L ) ; know Gilbert 's disease Uncontrolled severe infection , Severe pain ( VAS &gt; 5/10 ) uncontrollable opioid therapy Symptomatic sensorimotor peripheral neuropathy Pregnant lactating patient patient sex childbearing potential use adequate contraception method Patient receive receive experimental therapy within 4 week prior enter study participate another clinical study experimental drug Known hypersensitivity component treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>